NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.84 -0.52 (-0.62%) GOLD FUTURES
2,328.90 -13.20 (-0.56%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,557.22 -1,768.34 (-3.32%)
Roche Holding AG (0QQ6.L)
| Previous close | 248.89 |
| Open | 242.80 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 238.80 - 243.31 |
| 52-week range | 236.00 - 317.40 |
| Volume | |
| Avg. volume | 9,031 |
| Market cap | 2.066B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 0.15 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
- Reuters
UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
Roche confirmed ambitions to return to sales growth this year on a continued boost from eye drug Vabysmo, after first-quarter sales slipped by 6% on the loss on COVID-19-related revenue. Quarterly sales fell to 14.4 billion Swiss francs ($15.80 billion), the family-controlled drugmaker said in a statement on Wednesday, hurt also by a strong Swiss franc that weighed on overseas revenue but in line with analysts expectations. Roche, which does not disclose quarterly earnings, said the rest of the year would no longer be burdened by year-earlier comparisons that were inflated by COVID-related sales.
- Zacks
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
